- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Clinical Subjects Office Chief Steps Down
17 October 2002 (All day)
After heading efforts to beef up patient safety in clinical trials for 2 years, the director of the federal Office for Human Research Protections (OHRP) is returning to academia in December. Greg Koski, a Harvard University anesthesiologist, came in to head the newly promoted OHRP within the Department of Health and Human Services (HHS) after a death in a gene therapy trial brought increased scrutiny of patient safety in research.
Since Koski's arrival, OHRP has cracked down on several institutions for violating patient safety protections and has cleared a backlog of investigations. Koski also developed what he calls a "proactive, performance-based system" for helping institutions do a better job. The idea is to have institutions grade themselves on their patient protections programs, just as factories strive to achieve gold stars for quality control, Koski says. A report earlier this month from the Institute of Medicine helps complete the "road map" on where to go next, he notes, partly by calling for voluntary accreditation of human subjects protection programs.
University of Kansas bioethicist Mary Faith Marshall calls the quality-assurance program "fantastic" and says Koski was a "tireless ambassador," traveling the country to win over "the hearts of many people in the research community" with his message of "shared goals." Some patient advocates, however, are pushing for mandatory standards instead of the voluntary approach that Koski has supported.
Koski, who will serve through the end of November, insists that his departure "is not a political decision in any way" and notes that he was on a 2-year leave from Harvard in Massachusetts, where his family still lives. However, some observers suggest that a lack of support at HHS might have helped speed his return to academe. Recently, HHS abruptly decided to let the charter of OHRP's advisory committee lapse, a decision that Marshall, the panel's chair, says "shocked and dismayed" members and surprised Koski as well. HHS is now reforming the group and is said to be expanding its charter to include protection of fetuses and embryos, in line with the antiabortion views of the Bush Administration.